StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
GPTHEALTH.BO$151.30+6.10%
Fair $151.30+0.0%

GPTHEALTH.BO

GPT Healthcare Limited

Healthcare / Medical Care FacilitiesBSE

$151.30

+8.70 (+6.10%)

Fairly Valued+0.0%Fair Value $151.30Fund rank 35/100 · Data gapFallback financials|
SA 53/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $393.4M · quality 70.0/100

Data gap 35/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 72/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

53/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · GPTHEALTH.BOLocal privado en este navegador · GPT Healthcare Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$12.4B

P/E

29.4x

↑

EV/EBITDA

14.7x

↑

ROE

15.7%

↑

Gross Margin

63.1%

↑

Debt/Equity

0.34

↑
52-Week Range$151
$114$185

TradingView lightweight chart

GPTHEALTH.BO price, volumen y niveles de valoración

Último $151.30Periodo -24.6%
Fair value: $151.30

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+9.5%

FCF CAGR

-11.3%

FCF margin

8.3%

FCF / Net income

0.93x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $4.73B · net income $422.2M · FCF $393.4M

2023-FY → 2026-FY

Gross margin

63.1%+0.3% pts

Operating margin

12.1%-4.4% pts

Net margin

8.9%-1.9% pts

FCF margin

8.3%-7.3% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$4.73B$4.73B$4.07B$4.00B$3.60B
Net Income$422.2M$422.2M$499.2M$477.7M$390.1M
EBITDA$901.3M$901.3M$918.5M$925.2M$793.2M
EPS5.155.156.085.964.75
Gross Margin63.1%63.1%62.7%63.1%62.9%
Operating Margin12.1%12.1%15.8%18.0%16.5%
Net Margin8.9%8.9%12.3%12.0%10.8%
Balance Sheet
Debt/Equity0.340.340.140.140.50
Current Ratio1.121.12———
Cash Flow
Free Cash Flow$393.4M$393.4M$174.7M$494.3M$564.1M
Returns
ROE15.7%15.7%20.1%21.9%23.6%
Valuation
P/E29.3829.3827.7030.65—
EV/EBITDA14.7314.7315.4216.12—
P/B4.604.605.586.70—
Growth & Yield
Revenue Growth16.1%16.1%1.9%10.9%—
EPS Growth-15.3%-15.3%2.0%25.4%—
Dividend Yield2.1%2.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

37.6%

muy exigente

EPS terminal req.

$13.43

Spread vs growth

-52.9%

5Y implied EPS CAGR

25.8%

muy exigente

EPS terminal req.

$16.24

Spread vs growth

-41.1%

10Y implied EPS CAGR

17.6%

exigente

EPS terminal req.

$26.16

Spread vs growth

-32.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +0.9%

Total return

+0.9%

Start / end P/E

25.2x → 29.4x

EPS bridge

6.08 → 5.15

Residual

-2.5%

EPS growth-15.3%
Multiple rerating+16.6%
Dividend+2.1%
Residual / FX / buybacks / cross-term-2.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.